Goldman Sachs Group Inc Aquestive Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 876,537 shares of AQST stock, worth $2.45 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
876,537
Previous 222,687
293.62%
Holding current value
$2.45 Million
Previous $1.11 Million
179.96%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding AQST
# of Institutions
121Shares Held
43.3MCall Options Held
504KPut Options Held
148K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$27.5 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$15.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$12.2 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY2.63MShares$7.36 Million1.54% of portfolio
-
Franklin Resources Inc San Mateo, CA2.13MShares$5.98 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $149M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...